

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1626

BOLD, Guido et al.

Examiner: SHAMEEM, Golam M.

INTERNATIONAL APPLICATION NO: PCT/EP2004/012892

FILED: 12 November 2004

U.S. APPLICATION NO: 10/578,826

35 USC §371 DATE: 20 November 2006

FOR: Thiazole and Pyrazole Derivatives as FLT-3 Kinase Inhibitors

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO ELECTION/RESTRICTION


Sir:

In response to the Restriction Requirement mailed on 15 June 2009, a response to which is due 15 November 2009 with the enclosed four month extension of time fee, Applicants elect to prosecute claims of group I without traverse. Applicants further elect the species of Example 5, namely [5-(4-Methoxy-phenyl)-thiazol-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine, for prosecution.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-7347


Mark E. Baron
Attorney for Applicants
Reg. No. 46,150

Date: 13 November 2009